Evaluation and management of platelet transfusion refractoriness

被引:10
作者
Youk, Hee-Jeong [1 ]
Hwang, Sang-Hyun [1 ]
Oh, Heung-Bum [1 ]
Ko, Dae-Hyun [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Lab Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
关键词
Platelet transfusion refractoriness; Platelet transfusion; Human leukocyte antigen; H LA-matched; Platelet; ACID TREATMENT; ALLOIMMUNIZATION; ELIMINATE; SURFACE; IMMUNE; COUNT; SLOW;
D O I
10.5045/br.2022.2021229
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common is human leukocyte antigen (HLA) class I molecules. PTR caused by anti-HLA antibodies is usually managed by transfusing HLA-matched platelets. Therefore, it is important, especially for hemato-oncologists who frequently perform transfusion, to accurately diagnose whether the cause of platelet transfusion failure is alloimmune or non-immunological when determining the treatment direction for the patient. In this review, we discuss the definitions, causes, countermeasures, and prevention methods of PTR.
引用
收藏
页码:6 / 10
页数:5
相关论文
共 31 条
[1]   Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management [J].
Aster, R. H. ;
Curtis, B. R. ;
McFarland, J. G. ;
Bougie, D. W. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (06) :911-918
[2]   Platelet transfusion refractoriness: how do I diagnose and manage? [J].
Cohn, Claudia S. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) :527-532
[3]   RELATIVE IMPORTANCE OF IMMUNE AND NONIMMUNE CAUSES OF PLATELET REFRACTORINESS [J].
DOUGHTY, HA ;
MURPHY, MF ;
METCALFE, P ;
ROHATINER, AZS ;
LISTER, TA ;
WATERS, AH .
VOX SANGUINIS, 1994, 66 (03) :200-205
[4]   Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets [J].
Eriksson, L ;
Kristensen, J ;
Olsson, K ;
Bring, J ;
Hogman, CF .
VOX SANGUINIS, 1996, 70 (02) :69-75
[5]   ROLES OF PROTHROMBIN ACTIVITY, HEPARIN-PROTAMINE TITER AND PLATELET CONCENTRATION IN BLEEDING OF LEUKEMIA [J].
FREEMAN, G ;
HYDE, JS .
BLOOD, 1952, 7 (03) :311-325
[6]   RESPONSE TO REPEATED PLATELET TRANSFUSION FROM SAME DONOR [J].
FREIREICH, EJ ;
MANTEL, N ;
KLIMAN, A ;
GAYDOS, LA ;
FREI, E .
ANNALS OF INTERNAL MEDICINE, 1963, 59 (03) :277-+
[7]   QUANTITATIVE RELATION BETWEEN PLATELET COUNT AND HEMORRHAGE IN PATIENTS WITH ACUTE LEUKEMIA [J].
GAYDOS, LA ;
MANTEL, N ;
FREIREICH, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1962, 266 (18) :905-&
[8]   Platelet kinetics after slow versus standard transfusions: A pilot study [J].
Habibi, Abbas ;
Esfandbod, Mohsen ;
Ghafari, Mohammad Hossein ;
Khashayar, Patricia ;
Najafi, Atabak ;
Moharari, Reza Shariat .
UPSALA JOURNAL OF MEDICAL SCIENCES, 2011, 116 (03) :212-215
[9]   CAUSES OF DEATH IN ACUTE LEUKEMIA - A 10-YEAR STUDY OF 414 PATIENTS FROM 1954-1963 [J].
HERSH, EM ;
BODEY, GP ;
NIES, BA ;
FREIREIC.EJ .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 193 (02) :105-&
[10]   Platelet transfusion refractoriness [J].
Hod, Eldad ;
Schwartz, Joseph .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (03) :348-360